Text Size

Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease

This study has been completed.
Sponsor:
Information provided by:
Isfahan University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01239979
First received: November 12, 2010
Last updated: December 21, 2010
Last verified: January 2009
History of Changes
  Purpose

The investigators sought to assess whether plasma myeloperoxidase (MPO) levels differ among patients with stable and unstable CAD patients and control subjects, and correlate with inflammatory and clinical risk factors such as ox-LDL, NO,leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine in the patients.


Condition
Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Evaluation of the Association Between Myeloperoxidase Levels and Cardiovascular Risk Factors in Patients With Coronary Artery Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Isfahan University of Medical Sciences:

Primary Outcome Measures:
  • Plasma myeloperoxidase levels [ Time Frame: 3 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical risk factors [ Time Frame: 3 month ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Plasma


Enrollment: 150
Study Start Date: January 2009
Study Completion Date: November 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Stable, Unstable , control

Detailed Description:

Elevation of the leukocyte enzyme myeloperoxidase (MPO) in stable coronary artery disease (CAD) patients in contrast to unstable CAD patients is controversial and its relationship with some inflammatory and noninflammatory markers such as oxidized LDL (ox-LDL) and nitric oxide (NO) in the CAD patients has not been evaluated yet. Evaluation of these relationships is the aim of the study.Also the relationships between MPO and some other inflammatory biomarker such as leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine are examined. This study includes 50 stable CAD, 50 unstable CAD patients and 50 controls. Plasma MPO, ox-LDL, leptin, adiponectin, sPLA2 levels are determined using enzyme immunoassay.Homocysteine and 3-nitrotyrosine are measured using HPLC-fluorescence method. Plasma total NO and other risk factors such as lipid profile, hypertension, smoking, diabetes mellitus and familial history of CAD are also determined in the patients. Results are statistically analysed and the association between all markers are assessed.

  Eligibility

Ages Eligible for Study:   35 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

All subjects are diagnosed angiographically following chest pain, clinical manifestations or suspected changes on ECG at Isfahan Cardiovascular Research Center in Iran

Criteria

Inclusion Criteria:

  • Stable and unstable patients with angiographically documented coronary artery disease.
  • Control subjects without angiographically documented coronary artery disease.

All subjects Exclusion Criteria:

  • Patients with recent (with in 6 month) myocardial infarction or cardiovascular events,
  • surgery (with in 3 month),
  • cancer and
  • infective or inflammatory diseases were not included in the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01239979

Locations
Iran, Islamic Republic of
Isfahan Cardiovascular Research Center
Isfahan, Iran, Islamic Republic of, 81465-1148
Sponsors and Collaborators
Isfahan University of Medical Sciences
Investigators
Study Director: Saedzaaldin Samsamshariat, PhD - Clinical Biochemistry Department, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
  More Information

No publications provided

Responsible Party: Gholam Basati, School of pharmacy and pharmaceutical sciences
ClinicalTrials.gov Identifier: NCT01239979     History of Changes
Other Study ID Numbers: 388417
Study First Received: November 12, 2010
Last Updated: December 21, 2010
Health Authority: Iran: Ministry of Health

Keywords provided by Isfahan University of Medical Sciences:
coronary artery disease

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
 Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 19, 2013